Sionna Therapeutics, Inc. (SION) 10-Year Financial Performance & Capital Metrics

SION • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.Show more

Revenue $0
EBITDA -$70M -40.5%
Net Income -$62M -30.5%
EPS (Diluted) -1.40 -30.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-66.16%

5Y Avg-66.16%

3Y Avg-66.16%

Latest-64.36%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	668K
COGS % of Revenue	-	-	-
Gross Profit+	0	0	-668K
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	41.37M	50.33M	69.89M
OpEx % of Revenue	-	-	-
Selling, General & Admin	6.77M	9.71M	13.27M
SG&A % of Revenue	-	-	-
Research & Development	34.6M	40.63M	57.29M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	-668K
Operating Income+	-41.37M	-50.33M	-70.56M
Operating Margin %	-	-	-
Operating Income Growth %	-	-0.22%	-0.4%
EBITDA+	-41.25M	-49.75M	-69.89M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-0.21%	-0.4%
D&A (Non-Cash Add-back)	122K	583K	668K
EBIT	-41.37M	-50.33M	-70.56M
Net Interest Income+	1.13M	2.77M	8.17M
Interest Income	1.13M	2.77M	8.17M
Interest Expense	0	0	0
Other Income/Expense	1.13M	3.07M	8.87M
Pretax Income+	-40.24M	-47.26M	-61.69M
Pretax Margin %	-	-	-
Income Tax+	0	0	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-40.24M	-47.26M	-61.69M
Net Margin %	-	-	-
Net Income Growth %	-	-0.17%	-0.31%
Net Income (Continuing)	-40.24M	-47.26M	-61.69M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-0.91	-1.07	-1.40
EPS Growth %	-	-0.17%	-0.31%
EPS (Basic)	-0.91	-1.07	-1.40
Diluted Shares Outstanding	44.12M	44.12M	44.12M
Basic Shares Outstanding	44.12M	44.12M	44.12M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	83.83M	39.21M	150.99M
Cash & Short-Term Investments	82.61M	38.52M	147.54M
Cash Only	54.84M	38.52M	37.79M
Short-Term Investments	27.77M	0	109.75M
Accounts Receivable	0	0	0
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	1.22M	686K	3.46M
Total Non-Current Assets+	3.54M	12.74M	34.76M
Property, Plant & Equipment	2.57M	11.73M	10.3M
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	20.5M
Other Non-Current Assets	962K	1.01M	3.96M
Total Assets+	87.37M	51.95M	185.75M
Asset Turnover	-	-	-
Asset Growth %	-	-0.41%	2.58%
Total Current Liabilities+	8.25M	8.04M	10.42M
Accounts Payable	557K	719K	1.19M
Days Payables Outstanding	-	-	648.04
Short-Term Debt	0	0	0
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	1.95M	3.11M	2.97M
Current Ratio	10.16x	4.88x	14.49x
Quick Ratio	10.16x	4.88x	14.49x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	149.04M	158.79M	339.05M
Long-Term Debt	0	0	0
Capital Lease Obligations	0	9.75M	8.68M
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	149.04M	149.04M	330.37M
Total Liabilities	157.29M	166.83M	349.46M
Total Debt+	0	10.48M	9.75M
Net Debt	-54.84M	-28.04M	-28.04M
Debt / Equity	-	-	-
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-	-	-
Total Equity+	-69.92M	-114.88M	-163.71M
Equity Growth %	-	-0.64%	-0.43%
Book Value per Share	-1.58	-2.60	-3.71
Total Shareholders' Equity	-69.92M	-114.88M	-163.71M
Common Stock	2K	2K	5K
Retained Earnings	-72.14M	-119.4M	-181.09M
Treasury Stock	0	0	0
Accumulated OCI	-16K	0	368K
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-36.07M	-43.7M	-52.79M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-0.21%	-0.21%
Net Income	-40.24M	-47.26M	-61.69M
Depreciation & Amortization	122K	583K	668K
Stock-Based Compensation	1.69M	2.26M	3.71M
Deferred Taxes	0	0	0
Other Non-Cash Items	-400K	1.5M	7.6M
Working Capital Changes	2.76M	-783K	-3.08M
Change in Receivables	0	0	0
Change in Inventory	0	0	0
Change in Payables	-1.51M	162K	467K
Cash from Investing+	-29.26M	27.35M	-126.91M
Capital Expenditures	-1.87M	-1.12M	-27K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	0
Cash from Financing+	110.86M	31K	178.97M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	64K	31K	0
Net Change in Cash	-	-	-
Free Cash Flow+	-37.94M	-44.81M	-52.81M
FCF Margin %	-	-	-
FCF Growth %	-	-0.18%	-0.18%
FCF per Share	-0.86	-1.02	-1.20
FCF Conversion (FCF/Net Income)	0.90x	0.92x	0.86x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2022	2023	2024
FCF Conversion	0.90x	0.92x	0.86x

Frequently Asked Questions

Growth & Financials

Sionna Therapeutics, Inc. (SION) grew revenue by 0.0% over the past year. Growth has been modest.

Sionna Therapeutics, Inc. (SION) reported a net loss of $70.7M for fiscal year 2024.

Dividend & Returns

Sionna Therapeutics, Inc. (SION) had negative free cash flow of $61.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener